Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens

Clinical Therapeutics

Volumn 32, Issue 5, 2010, Pages 915-919

  Meie, Giuseppe ^a   Pinna, Salvatore ^a   Melpignano, Angela ^a   Quarta, Giovanni ^a  

^a PERRINO HOSPITAL   (Italy)

Author keywords

Bortezomib based regimens; Plasma cell leukemia; Survival

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHOTREXATE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; DRUG RESPONSE; EPISTAXIS; FEMALE; FEVER; HEPATOMEGALY; HUMAN; LEUKOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMA CELL LEUKEMIA; SPLENOMEGALY; SYMPTOM; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; PYRAZINES; RETROSPECTIVE STUDIES;

EID: 77954790973     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.05.008     Document Type: Article

References (15)

1. Bladé J, Kyle RA Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukaemia. Hematol Oncol Clin North Am. 1999, 13:1259-1272.
2. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: Report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005, 78:288-294.
3. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002, 81:362-367.
4. Jiménez-Zepeda VH, Dominguez VJ Plasma cell leukemia: A rare condition. Ann Hematol. 2006, 85:263-267.
5. Kyle RA, Maldonado JE, Bayrd ED Plasma cell leukemia. Report on 17 cases. Arch Intern Med. 1974, 133:813-818.
6. Esparis-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer. 2005, 114:665-667.
7. Grassinger J, Südhoff T, Andreesen R, Hennemann B Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol. 2006, 85:132-133.
8. Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukaemia. Leuk Lymphoma. 2006, 47:1670-1673.
9. Ataergin S, Arpaci F, Kaya A, et al. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia [published correction appears in Am J Hematol. 2007;82:89]. Am J Hematol 2006, 81:987-988.
10. Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer. 2007, 109:2285-2290. GISMM Cooperative Group, GISL Cooperative Group, GIMEMA Cooperative GroupGIMEMA Cooperative Group.
11. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma [published corrections appear in Leukemia. 2007;21:1134 and Leukemia. 2006;20:2220]. Leukemia 2006, 20:1467-1473. International Myeloma Working Group.
12. Durie BG, Salmon SE A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975, 36:842-854.
13. Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: A study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Français de Cytogénétique Hematologique. Blood. 2001, 97:822-825.
14. Mattioli M, Agnelli L, Fabris S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene. 2005, 24:2461-2473.
15. Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005, 11:3661-3667.